TP53 and leukemia: However, Bezerra et al. study showed that the TP53 Pro/Pro genotype was correlated with a higher risk of leukemia and favorable outcome in Brazilian AML patients who received conventional therapy, especially those with intermediate cytogenetic risk [331].